Floatz Rating
C37/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06863233CT.gov A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Zirconium Zr 89 Crefmirlimab Berdoxam (this asset) | Memorial Sloan Kettering Cancer Center | P1 | C · 37 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BBB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Docetaxel | SWOG Cancer Research Network | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Zirconium Zr 89 Crefmirlimab Berdoxam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2/3 | B · 58 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2 | CCC · 52 |
| Urinary Bladder Neoplasm | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Zirconium Zr 89 Crefmirlimab Berdoxam in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/zirconium-zr-89-crefmirlimab-berdoxam-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →